Project Grant R01CA302918
Award Date 7/1/26
Completion Date 6/30/31
Dollars Obligated $737K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $1.71 million Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2025, through July 31, 2032. The award supports research into new approaches to targeting cell cycle proteins for cancer treatment, specifically addressing limitations of current cyclin-dependent kinase (CDK) inhibitors. The project focuses on three critical therapeutic...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $645,102 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective July 1, 2026, through June 30, 2031. The award funds fundamental research investigating the molecular mechanisms governing WEE1 kinase's transition between functioning as a cell cycle checkpoint enzyme and as a phosphorylation substrate. The research addresses a critical gap in cell cycle...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $110,190 Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), effective December 27, 2025 through June 30, 2028. The award supports biomedical training and research development in cancer biology, specifically focused on unraveling the mechanisms of neoantigen vaccine-induced epitope spreading (ES)—a phenomenon in which vaccine-primed tumor cell destruction...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Dana-Farber Cancer Institute, Inc. a Project Grant of $718,275 under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2026, through June 30, 2031. This award supports fundamental research investigating context-specific pathway dependencies of nuclear envelope (NE) proteins in brain cancer. The research employs a large-scale analysis framework called WEBSTER to assess how NE-associated proteins...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $483,395 Project Grant under the Cancer Treatment Research program (CFDA 93.395) beginning September 1, 2025, and concluding August 31, 2027. This research initiative focuses on investigating P300 and CBP (Cyclic AMP-Response Element Binding Protein) as novel therapeutic targets in renal cell carcinoma (RCC), specifically clear cell RCC (ccRCC). The project will examine the therapeutic potential...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $170,394 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) effective July 1, 2026, through June 30, 2028. This award supports biomedical research training and workforce development in cancer biology, specifically funding postdoctoral research investigating the epigenetic mechanisms underlying neuroendocrine lineage carcinomas. The research focuses on defining...
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $721,653 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded June 5, 2026, with completion scheduled for May 31, 2031. The award funds research into protein O-mannosylation as a therapeutic vulnerability in KIAA1549-BRAF-driven pediatric low-grade gliomas (PLGGs), which represent the most frequent solid tumors in childhood. The institute will...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary The Johns Hopkins University received a $643,861 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) effective June 1, 2026 through May 31, 2031. This five-year research initiative aims to uncover the molecular mechanisms by which translocation renal cell carcinoma (TRCC) fusion oncoproteins drive disease progression, with the ultimate goal of identifying potential drug targets and critical...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $482,236 to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2025, with a project completion date of July 31, 2030. This investigator-initiated Phase 2 clinical trial will evaluate the safety and efficacy of combining trastuzumab deruxtecan (T-DXD), an antibody-drug conjugate, with the anti-EGFR (epidermal growth factor receptor)...